Coronavirus Immunotherapy Consortium

The Coronavirus Immunotherapy Consortium (CoVIC) is a global public-private partnership based out of the Center for Infectious Disease and Vaccine Research at the La Jolla Institute for Immunology.1) CoVIC's principal investigator is Erica Saphire.

The stated purpose of the consortium is to “accelerate discovery, optimization, and delivery of life-saving antibody-based therapeutics against SARS-CoV-2.”2)

History

CoVIC is a continuation of the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), which was previously formed to collect donations of antibodies against Ebola and Lassa viruses.3)

Organization

Partners

Funding

CoVIC is funded by the COVID-19 Therapeutics Accelerator, GHR Foundation and the National Institute of Allergy and Infectious Diseases (NIAID).5) NIAID funding came as a supplement to a Center For Excellence in Therapeutic Research (CETR) to Dr. Saphire (U19 142790-02S1).

1)
Contact. Coronavirus Immunotherapy Consortium. Retrieved January 19, 2023, from https://web.archive.org/web/20230119213903/https://covic.lji.org/contact/
2) , 5)
About CoVIC. Coronavirus Immunotherapy Consortium. Retrieved January 19, 2023, from https://web.archive.org/web/20230119213917/https://covic.lji.org/about/
3)
CoVIC Formation and Mission. Coronavirus Immunotherapy Consortium. Retrieved January 19, 2023, from https://archive.ph/9XgOh
4)
Partners. Coronavirus Immunotherapy Consortium. Retrieved January 19, 2023, from https://archive.ph/gsq0B
Back to top